C 1311

Drug Profile

C 1311

Alternative Names: C-1311; Imidacrine; Imidazoloacridine; NSC 645809; Symadex; Symadex Pathfinder; XLS-002

Latest Information Update: 10 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Bradford
  • Developer Antisoma
  • Class Aminoacridines; Antineoplastics; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Colorectal cancer; Lymphoid leukaemia; Multiple sclerosis; Rheumatoid arthritis; Solid tumours; Ulcerative colitis

Most Recent Events

  • 11 Jun 2008 Xanthus Pharmaceuticals has been acquired and merged into Antisoma
  • 03 Jun 2008 Final adverse events data from a phase I trial in patients with advanced solid tumours presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
  • 03 Jun 2008 Efficacy data from a phase II trial in advanced breast cancer presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top